Trexquant Investment LP Purchases 45,235 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Trexquant Investment LP increased its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 592.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,876 shares of the company's stock after buying an additional 45,235 shares during the period. Trexquant Investment LP owned 0.09% of Structure Therapeutics worth $1,434,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. ANTIPODES PARTNERS Ltd raised its holdings in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares in the last quarter. GAMMA Investing LLC raised its stake in Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Structure Therapeutics in the fourth quarter valued at about $40,000. Assetmark Inc. lifted its position in Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after purchasing an additional 953 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in Structure Therapeutics during the fourth quarter worth about $113,000. 91.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on GPCR shares. JMP Securities restated a "market outperform" rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. William Blair started coverage on Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating for the company. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $81.29.

Remove Ads

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR traded down $0.16 during midday trading on Tuesday, hitting $18.80. 248,679 shares of the stock were exchanged, compared to its average volume of 870,164. The business's 50-day moving average price is $20.74 and its 200 day moving average price is $28.95. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -25.53 and a beta of -1.35. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, sell-side analysts expect that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.